Upload
griselda-lynch
View
219
Download
1
Tags:
Embed Size (px)
Citation preview
An Introduction to
Hematologic Malignancies
Francesco Lo-Coco
Università Tor Vergata, Roma
Summer Medical School
Tor Vergata University, July 2011
Oncohematology
• Dealing with malignant tumors of the hematopoietic system
• Tumors affecting blood and/or bone marrow and/or lymphoid organs
• Synonim: hematologic malignancies
Hematologic Malignancies
• Systemic diseases (with few exceptions)
• Laboratory assessment of paramount relevance for diagnosis and management
Hematologic Malignancies
• Leukemias
• Lymphomas
• Myeloproliferative syndromes
• Multiple myeloma
Leukemia
• Metastatic disease (by definition)
• Early diagnosis (almost) irrelevant
• Etiology mostly unknown
Demographics of Leukemia Types
ALL11%
CLL26%
AML31%
CML15%
others17%
Total Reported Cases = 31,500Sources from Leukemia, Lyphoma, Myeloma Facts 2001
CLL=Chronic Lymphocytic
ALL=Acute Lymphoblastic
CML=Chronic Mylogenous
AML=Acute Mylogenous
Leukemia
• Metastatic disease (by definition)
• Early diagnosis (almost) irrelevant
• Etiology mostly unknown
Leukemia: a paradigm for research
• Tumor cells easily and promptly available
• Can be cultured, manipulated, stored and thawed as viable cells
• Biomarker detection of paramount relevance to guide therapy
Laboratory characterization of blood tumors
• Morphologic exam (blood/marrow smear)
• Immunophenotype
• Cytogenetics
• Molecular biology
Biomarkers in Leukemia
• Diagnostic hallmarks or refinement
• Prognostic markers
• Minimal residual disease (MRD)
• Targeted therapy
Therapeutic targets in APL
AcAcAc
RARa
PMLPML
RARa
CD33
Arsenic trioxide
Anthracyclines
Histone deacetylase inhibitors
FLT3 inhibitors
Gemtuzumab- Ozogamicin (GO)
HuM195
Sin3A
N-CoR/SMRT
HDAC
FLT3
Caspase 3
Caspase 9
ROSApaf
Retinoic Acid
Targeted therapy with retinoic acid for APL
+ All-trans Retinoic Acid
1. Differentiating effect of ATRA
Huang ME, Blood 1988; Castaigne S, Blood 1990; Borrow J, Science 1990; Longo L, J Exp Med 1990; de Thé H, Nature 1990
2. Cloning of PML/RARA
The landmark discoveries that revolutionized APL therapy
Copyright ©2004 American Society of Hematology. Copyright restrictions may apply.
Sanz, M. A. et al. Blood 2004;103:1237-1243
2000-2010
Pre-ATRA era
Outcome results in APL prior and after ATRA
Sanz et al. Blood, 2009
From Confucius to differentiation therapy
ATRA
G. Lo Coco, Westminster School Hook Magazine. May 2011
“If you use laws to direct the people, and punishments to control them, they will merely try to evade the laws, and will have no sense of shame.
But if by virtue you guide them, and by the rites you control them, there will be a sense of shame and of right.”
Confucius
Targeted therapy with imatinib in CML
Outcome of AML in older adults (60+ yrs)
(n=3541)
Outcome of AML in younger adults (15-59 yrs)
(n=7704)
Lymphomas
• Hodgkin’s
• Non Hodgkins (B-cell or T-cell)
Lymphomas
•Highly curable malignancies in oncological practice: 90%of Hodgkin ’s disease 40-50%of high-grade NHL
•Malignant disease of the lymphoid system highly heterogeneous, both histologically and clinically
• 5th most frequently diagnosed cancer in both sexes
• males > females
• incidence– NHL increasing– Hodgkin lymphoma stable
Epidemiology of lymphomas
Frequencies of different lymphomas
HodgkinLymphoma11%
NHL
Diffuse large B-cell
Follicular
Other NHL
Non-Hodgkin Lymphomas
~85% of NHL are B-lineage
Age distribution of Hodgkin lymphoma
Indolent (35%)
Diffuse largeB-cell (31%)
Mantle cell (6%)
Peripheral T-cell (6%)
Other subtypes with a frequency 2% (9%)
Frequency of NHL Subtypes in Adults
Composite lymphomas (13%)
Lymphomagenesis
Chromosomal translocations in NHL
Chromosomal translocations in NHL
• Plasma cell malignancy: clonal proliferation of plasma cells by monoclonal protein
Multiple myeloma
• 1% of all malignancies
• 10% of hematologic malignancies
Epidemiology
Multiple myeloma: hallmarks
Presence of monoclonal protein Anemia Renal failure Bone destruction (lytic lesions) Compressive neuropathy Hypercalcemia Increased risk of infection